Matched cohort study compares oncologic outcomes and kidney function in non-metastatic pT3a renal cell carcinoma patients, indicating a potential alternative.
MIS-PN provided comparable mild term oncologic outcomes to MIS-RN while offering superior renal function preservation. MIS-PN may be a viable option for selected T3a RCC patients when nephron preservation is indicated.
No takes yet. Share an insight, caveat, or question.
Zou et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: